BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 35496822)

  • 1. The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions.
    Lombardi C; Berti A; Cottini M
    Curr Res Immunol; 2022; 3():42-53. PubMed ID: 35496822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
    Nagase H; Ueki S; Fujieda S
    Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.
    Roufosse F
    Front Med (Lausanne); 2018; 5():49. PubMed ID: 29682504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
    Harish A; Schwartz SA
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The multiple functions and subpopulations of eosinophils in tissues under steady-state and pathological conditions.
    Kanda A; Yun Y; Bui DV; Nguyen LM; Kobayashi Y; Suzuki K; Mitani A; Sawada S; Hamada S; Asako M; Iwai H
    Allergol Int; 2021 Jan; 70(1):9-18. PubMed ID: 33243693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophilic respiratory disorders and the impact of biologics.
    Bernstein JS; Wechsler ME
    Curr Opin Pulm Med; 2023 May; 29(3):202-208. PubMed ID: 36866734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting eosinophils: severe asthma and beyond.
    Caminati M; Menzella F; Guidolin L; Senna G
    Drugs Context; 2019; 8():212587. PubMed ID: 31391853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple Biological Aspects of Eosinophils in Host Defense, Eosinophil-Associated Diseases, Immunoregulation, and Homeostasis: Is Their Role Beneficial, Detrimental, Regulator, or Bystander?
    Kanda A; Yasutaka Y; Van Bui D; Suzuki K; Sawada S; Kobayashi Y; Asako M; Iwai H
    Biol Pharm Bull; 2020; 43(1):20-30. PubMed ID: 31902927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes.
    Olaguibel JM; Sastre J; Rodríguez JM; Del Pozo V
    J Investig Allergol Clin Immunol; 2022 Jun; 32(3):165-180. PubMed ID: 35522053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eosinophils and childhood asthma.
    Choi BS
    Clin Exp Pediatr; 2021 Feb; 64(2):60-67. PubMed ID: 33445830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eosinophils and eosinophilic immune dysfunction in health and disease.
    Jackson DJ; Akuthota P; Roufosse F
    Eur Respir Rev; 2022 Mar; 31(163):. PubMed ID: 35082127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
    Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
    Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eosinophilic airway diseases: basic science, clinical manifestations and future challenges.
    Janson C; Bjermer L; Lehtimäki L; Kankaanranta H; Karjalainen J; Altraja A; Yasinska V; Aarli B; Rådinger M; Hellgren J; Lofdahl M; Howarth PH; Porsbjerg C
    Eur Clin Respir J; 2022; 9(1):2040707. PubMed ID: 35251534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 innate lymphoid cells: A novel biomarker of eosinophilic airway inflammation in patients with mild to moderate asthma.
    Liu T; Wu J; Zhao J; Wang J; Zhang Y; Liu L; Cao L; Liu Y; Dong L
    Respir Med; 2015 Nov; 109(11):1391-6. PubMed ID: 26459159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Sinonasal Histopathological Changes in Biological Treatment of Eosinophilic Chronic Rhinosinusitis.
    Ho J; Alvarado R; Rimmer J; Sewell WA; Walter S; Earls P; Campbell RG; Sacks R; Kalish LH; Harvey RJ
    Am J Rhinol Allergy; 2022 Jan; 36(1):72-80. PubMed ID: 34096329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
    Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.
    Kelly EA; Esnault S; Liu LY; Evans MD; Johansson MW; Mathur S; Mosher DF; Denlinger LC; Jarjour NN
    Am J Respir Crit Care Med; 2017 Dec; 196(11):1385-1395. PubMed ID: 28862877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.